Impact of tumor size on survival outcome in metastatic renal cell carcinoma patients (mRCC) treated with targeted therapy.

被引：0

作者：

Xie, Wanling

DiNatale, Renzo

Hakimi, A. Ari

Donskov, Frede

Porta, Camillo

Reaume, M. Neil

Basappa, Naveen S.

Hansen, Aaron Richard

Rini, Brian I.

Beuselinck, Benoit

Bjarnason, Georg A.

Srinivas, Sandy

Brugarolas, James

Rha, Sun Young

Wood, Lori

Lalani, Aly-Khan A.

Bosse, Dominick

Duquette, Audrey

Heng, Daniel Yick Chin

Choueiri, Toni K.

机构：

[1] Dana Farber Canc Inst, Boston, MA USA

[2] Mem Sloan Kettering Canc Ctr, New York, NY USA

[3] Aarhus Univ Hosp, Aarhus, Denmark

[4] IRCCS San Matteo Univ Hosp Fdn, Pavia, Italy

[5] Ottawa Hosp Canc Ctr, Ottawa, ON, Canada

[6] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada

[7] Princess Margaret Canc Ctr, Toronto, ON, Canada

[8] Cleveland Clin, Taussig Canc Inst, Cleveland, OH USA

[9] Univ Hosp Leuven, Leuven Canc Inst, Leuven, Belgium

[10] Univ Toronto, Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Toronto, ON, Canada

[11] Stanford Univ, Stanford, CA USA

[12] UT Southwestern Med Ctr, Dallas, TX USA

[13] Severance Hosp, Seoul, South Korea

[14] QEII Hlth Sci Ctr, Halifax, NS, Canada

[15] Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada

[16] Harvard Med Sch, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 06期

关键词：

D O I：

10.1200/JCO.2018.36.6_suppl.667

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

667

引用

页数：1